Open-label study of donepezil in chronic poststroke aphasia

Marcelo L. Berthier, Julían Hinojosa, María del Carmen Martín, Inmaculada Fernández

Neurology · 2003 · 117 citations · 4 references

Concepts

Abstract

Donepezil hydrochloride (HCl), a reversible acetylcholinesterase inhibitor with a selective central action, is effective in ameliorating language and cognitive deficits in dementia of Alzheimer type.1 Preliminary clinical experience in single-case studies and small numbers of patients suggests that donepezil HCl may also stabilize cognitive deficits associated with subcortical vascular dementia2 and may improve language deficits in patients with post-stroke aphasia.3,4⇓ We studied donepezil HCl in chronic poststroke aphasia. ### Subjects and study design. This was a 20-week open-label pilot study evaluating the effects of donepezil HCl in chronic poststroke aphasia. The patients were recruited from a language therapy center, where they received two weekly sessions of conventional speech–language therapy. All patients and their responsible family member signed an informed consent agreement. The study was approved by the ethical committees of the centers. The primary outcome measure was the mean score change from baseline to endpoints at weeks 4 and …

References

4